Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Notes Payables (2016 - 2021)

Historic Notes Payables for Sunshine Biopharma (SBFM) over the last 8 years, with Q4 2021 value amounting to $1.9 million.

  • Sunshine Biopharma's Notes Payables rose 13157.91% to $1.9 million in Q4 2021 from the same period last year, while for Dec 2021 it was $1.9 million, marking a year-over-year increase of 13157.91%. This contributed to the annual value of $1.9 million for FY2021, which is 13157.91% up from last year.
  • Latest data reveals that Sunshine Biopharma reported Notes Payables of $1.9 million as of Q4 2021, which was up 13157.91% from $330000.0 recorded in Q3 2021.
  • Sunshine Biopharma's 5-year Notes Payables high stood at $1.9 million for Q4 2021, and its period low was $183889.0 during Q1 2017.
  • Moreover, its 5-year median value for Notes Payables was $517217.5 (2020), whereas its average is $579101.3.
  • Within the past 5 years, the most significant YoY rise in Sunshine Biopharma's Notes Payables was 25716.33% (2017), while the steepest drop was 7445.97% (2017).
  • Sunshine Biopharma's Notes Payables (Quarter) stood at $596577.0 in 2017, then dropped by 29.65% to $419663.0 in 2018, then surged by 39.71% to $586307.0 in 2019, then soared by 39.94% to $820454.0 in 2020, then skyrocketed by 131.58% to $1.9 million in 2021.
  • Its last three reported values are $1.9 million in Q4 2021, $330000.0 for Q3 2021, and $330000.0 during Q2 2021.